AI assistant
SynAct Pharma Share Issue/Capital Change 2024
3114_rns_2024-12-30_270d9994-fb09-4230-92ef-a70eccc4d5cf.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Change in number of shares and votes in SynAct Pharma AB
SynAct Pharma AB (the "Company") announces that the number of shares and votes has increased by 5,191,003 as a result of the directed share issues resolved upon by the extraordinary general meeting on 13 December 2024.
Today, the last trading day of the month, the total number of shares and votes in the Company amounts to 46,487,467.
For further information, please contact: Jeppe Øvlesen, CEO SynAct Pharma Tel: +45 2844 7567 Email: [email protected]
About SynAct Pharma AB
SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and anti-inflammatory activity in autoimmune and inflammatory diseases to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com.
This information is information that SynAct Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-12-30 18:45 CET.
Attachments Change in number of shares and votes in SynAct Pharma AB